Status:
RECRUITING
Multiomics Tumor Evolution Model of NSCLC
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Research Unit of Intelligence Diagnosis and treatment of early-stage non-small cell lung cancer, Chinese Academy of Medical Sciences
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomi...
Detailed Description
Lung cancer is the leading cause of cancer-related death globally. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and surgery is still the main treatment strategy. This study will ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old;
- Early-stage NSCLC patients underwent radical surgical resection;
- Sufficient tumor tissue and blood sample for study use;
- Available clinical-pathologic data, imaging data and follow-up date;
- Written informed consent.
Exclusion
- History of other malignant tumors;
- Evidence of distant metastasis before surgery;
- Insufficient tumor tissue or blood sample for study use;
- Clinical-pathologic data, imaging data or follow-up date is not available;
- Other judgments by the Investigator that the patient should not participate in the study.
Key Trial Info
Start Date :
April 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05352035
Start Date
April 20 2022
End Date
December 31 2026
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China